July 1, 2021 — The U.S. Food and Drug Administration (FDA) has cleared the Angel Medical Systems Inc. second-generation AngelMed Guardian device.
Implantable Cardiac Monitor (ICM)
Implantable cardiac monitors (ICM) are small electrophysiology (EP) devices that used for long-term monitoring of a patient's heart electrical activity to detect arrhythmias. The technology can eliminate the need for a bulkly external Holter monitor that requires wire leads attached to the patient. ICMs can be inserted under the skin during and office visit and record cardiac data continuously for up to 4.5 years.
-
-
May 14, 2021 — The U.S.
-
April 26, 2021 — Patients receiving an implantable cardioverter defibrillator (ICD) should be regularly screened for anxiety and depression, according to research presented at...
-
A few weeks ago, a patient of mine experienced a cardiac event — his heart stopped. Completely.
In the past decade there has been a proliferation of clinical-grade wearable monitors and implantable devices such as pacemakers, ICDs, implantable cardiac monitors, and new pacemaker-like devices that can control hypertension. In the near future, these devices will be tied into a body-wide internet of things for specific patients that can transmit patient data to clinicians wirelessly to enable an integrated, more robust form of telecardiology and telemedicine.
Feature | Telecardiology | July 23, 2021 | Victor Wollesen
Cardiovascular diseases are among the leading causes of death for people over 65 years old in North America and Europe...
News | Implantable Cardiac Monitor (ICM) | July 14, 2021
June 13, 2021 — Medtronic announced clinical trial results from the STROKE AF trial demonstrating the superiority of...
The FDA has cleared Angel Medical Systems' second-generation AngelMed Guardian device. The implantable cardiac device detects and warns patients if they are having an acute coronary syndrome (ACS) event, including silent heart attacks. The new, second-generation device is enhanced with ease-of-use adaptations and an updated, long life battery that could potentially double the life of the implanted device
News | Cardiac Diagnostics | July 01, 2021
July 1, 2021 — The U.S. Food and Drug Administration (FDA) has cleared the Angel Medical Systems Inc. second-generation...
Implicity provides a remote cardiac monitoring and research platform used by Independent Diagnostic Testing Facilities and medical centers to deliver high-quality care for patients with connected cardiac devices. On this platform, Implicity aggregates, normalizes and standardizes data from any implantable cardiac device across all manufacturers.
News | EP Lab | June 02, 2021
June 2, 2021 — Implicity, a leader in remote patient monitoring software and cardiac data management solutions,...
A device programmer showing the suspension of ICD therapies (orange bar, red arrow) with iPhone 12 laying over patient’s chest (green arrow) and fluoroscopy of iPhone 12 showing the circular magnet array (yellow arrow). Image from a small study at Henry Ford Hospital. Read the full study
News | EP Lab | May 14, 2021
May 14, 2021 — The U.S. Food and Drug Administration (FDA) is advising patients and caregivers to keep any consumer...
News | EP Lab | April 26, 2021
April 26, 2021 — Patients receiving an implantable cardioverter defibrillator (ICD) should be regularly screened for...
Integrating data from an array of implantable EP devices from different vendors can be difficult or require disconnected silos of data for different vendors. One solution that was recently introduced to integrate data from various vendors is the Optimize EP software, which allows viewing data from all device vendors in one platform to streamline workflows.
Feature | EP Lab | March 17, 2021 | By Maninder Bedi, M.D.
A few weeks ago, a patient of mine experienced a cardiac event — his heart stopped. Completely. However, his...
The Optimize EP CaRM software integrates data from several EP devices a patients may use and aggregate it into one location.
News | EP Lab | February 02, 2021
February 2, 2021 – Optimize EP, a digital health company focused on transforming cardiac care by improving the current...
With the FDA clearance of the Vital Data Sensor, Biotronik's Biomonitor IIIm features two-in-one detection, providing physicians the ability to monitor for early signs of potential life-threatening cardiac arrhythmias and body temperature increases potentially associated with fever.
News | Implantable Cardiac Monitor (ICM) | December 22, 2020
December 22, 2020 — The U.S. Food and Drug Administration (FDA) cleared Biotronik's Vital Data Sensor, which identifies...
Videos | EP Device Monitoring Systems | December 22, 2020
Robert Kowal, M.D., chief medical officer of the Medtronic cardiac rhythm and heart failure division, said there has...
The Linq II implantable cardiac monitor (ICM) system delivers improved device longevity compared to other ICMs and enhanced accuracy to correctly detect abnormal heart rhythms, simplifying the diagnosis and monitoring of patients. The new devices allows continuous cardiac monitoring for up to 4.5 years.
News | Implantable Cardiac Monitor (ICM) | July 07, 2020
July 7, 2020 – Medtronic announced it received U.S. Food and Drug Administration (FDA) clearance and European CE mark...
News | Implantable Cardiac Monitor (ICM) | June 29, 2020
June 29, 2020 — Boston Scientific received U.S. Food and Drug Administration (FDA) 510(k) clearance for the LUX-Dx ...
Videos | Wearables | January 09, 2020
The Consumer Electronic Show (CES) is the world's gathering place for consumer technologies, with more than 175,000...
Image courtesy of Flinders University
News | Implantable Cardiac Monitor (ICM) | July 09, 2019
July 9, 2019 — South Australian researchers are developing a tiny fiber-optic sensor, which has the potential to change...
News | Implantable Cardiac Monitor (ICM) | July 01, 2019
July 1, 2019 – Biotronik announced the European market release of its new injectable cardiac monitor (ICM), Biomonitor...
